Array adds partner for blood research
Terms of the deal were not disclosed.
Array (Nasdaq: ARRY) will screen its library of 300,000 small molecules to identify compounds of certain Global Blood targets. A target is the naturally existing cellular or molecular structure that the drug in development is meant to act on.
"We look forward to deploying our drug discovery platform and sharing our expertise with companies like Global Blood," said Kevin Koch, president and chief scientific officer for Array. "Our mutual goal is to accelerate the drug-discovery and development process by combining Global Blood's expertise in disease biology and computationally supported medicinal chemistry with Array's established drug discovery platform."
Brian W. Metcalf, acting chief scientific officer for Global Blood, said the collaboration is a complement to Global's drug-discovery research.
More breaking news...
Corgenix partners with Lily on diagnostics
EAGLE-Net plans to resume construction
The two companies will